2024年6月最新影响因子数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Cancer Communications CANCER COMMUN （此期刊被最新的JCR期刊SCIE收录） LetPub评分 7.0
52人评分
我要评分
声誉 8.1 影响力 6.1 速度 7.0 | |||||||||||||||||||||
| 期刊ISSN | 2523-3548 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| 2023-2024最新影响因子 （数据来源于搜索引擎） | 20.1 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2024年10月29日：16.899 | |||||||||||||||||||||
| 2023-2024自引率 | 1.50%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 16.7 | |||||||||||||||||||||
| JCI期刊引文指标 | 3.06 | |||||||||||||||||||||
| h-index | 暂无h-index数据 | |||||||||||||||||||||
| CiteScore （ 2024年最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | https://onlinelibrary.wiley.com/journal/25233548 | |||||||||||||||||||||
| 期刊投稿网址 | https://mc.manuscriptcentral.com/cac2 | |||||||||||||||||||||
| 期刊语言要求 | Language Manuscripts must be written in American English and be grammatically and linguistically correct. Authors should seek assistance with style, grammar and vocabulary if necessary. Your manuscript may also be sent back to you for revision if the quality of English language is poor. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Cancer Communications的语言要求，还能让Cancer Communications编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Cancer Communications编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | Yes | |||||||||||||||||||||
OA期刊相关信息 | 文章处理费：需要（ USD2800; GBP2100; EUR2400; ） 文章处理费豁免：查看说明 其他费用：没有 期刊主题关键词：clinical trials、epidemiology、cellular biology、cancer、molecular biology、genetics 相关链接：Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||
| 通讯方式 | 111 RIVER ST, HOBOKEN, USA, NJ, 07030-5774 | |||||||||||||||||||||
| 出版商 | Wiley | |||||||||||||||||||||
| 涉及的研究方向 | Biochemistry, Genetics and Molecular Biology-Cancer Research | |||||||||||||||||||||
| 出版国家或地区 | PEOPLES R CHINA | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||
| 出版年份 | 2018 | |||||||||||||||||||||
| 年文章数 | 46点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 65.32% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 86.96% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2023-2024年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 中国科学院《国际期刊预警 名单（试行）》名单 | 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2023年12月最新升级版） | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2022年12月升级版） |
| |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2021年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2523-3548%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 4 Weeks | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： | |||||||||||||||||||||
| 版面费/APC文章处理费信息 | 文章处理费：需要（ USD2800; GBP2100; EUR2400; ） 文章处理费豁免：查看说明 其他费用：没有 LetPub提供文章处理费（APC）支持服务，可以用人民币支付版面费啦！ | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Cancer Communications顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Targeting RAS mutants in malignancies: successes, failures, and reasons for hope Author: Yang, Hang; Zhou, Xinyi; Fu, Dongliang; Le, Chenqin; Wang, Jiafeng; Zhou, Quan; Liu, Xiangrui; Yuan, Ying; Ding, Kefeng; Xiao, Qian Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 1, pp. 42-74. DOI: 10.1002/cac2.12377 PubMed DOI |
| 2. | circCAPRIN1 interacts with STAT2 to promote tumor progression and lipid synthesis via upregulating ACC1 expression in colorectal cancer Author: Yang, Yufei; Luo, Dakui; Shao, Yang; Shan, Zezhi; Liu, Qi; Weng, Junyong; He, Weijing; Zhang, Ruoxin; Li, Qingguo; Wang, Ziliang; Li, Xinxiang Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 1, pp. 100-122. DOI: 10.1002/cac2.12380 PubMed DOI |
| 3. | Elevated neutrophil extracellular traps by HBV-mediated S100A9-TLR4/RAGE-ROS cascade facilitate the growth and metastasis of hepatocellular carcinoma Author: Zhan, Xi; Wu, Rui; Kong, Xue-Hua; You, Yan; He, Kun; Sun, Xiao-Yu; Huang, Yong; Chen, Wei-Xian; Duan, Liang Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 2, pp. 225-245. DOI: 10.1002/cac2.12388 PubMed DOI |
| 4. | Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination/degradation of STAT1 in a GTP binding-dependent modality Author: Zhang, Lu; Li, Qingya; Yang, Jing; Xu, Penghui; Xuan, Zhe; Xu, Jianghao; Xu, Zekuan Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 1, pp. 123-149. DOI: 10.1002/cac2.12386 PubMed DOI |
| 5. | Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions Author: Chen, Yu-Fei; Xu, Ying-ying; Shao, Zhi-Ming; Yu, Ke-Da Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 3, pp. 297-337. DOI: 10.1002/cac2.12387 PubMed DOI |
| 6. | Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration? Author: Feng, Ruimei; Su, Qingling; Huang, Xiaoyin; Basnet, Til; Xu, Xin; Ye, Weimin Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 1, pp. 75-86. DOI: 10.1002/cac2.12393 PubMed DOI |
| 7. | Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives Author: Fang, Zengli; Meng, Qingcai; Xu, Jin; Wang, Wei; Zhang, Bo; Liu, Jiang; Liang, Chen; Hua, Jie; Zhao, Yingjun; Yu, Xianjun; Shi, Si Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 1, pp. 3-41. DOI: 10.1002/cac2.12392 PubMed DOI |
| 8. | Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors Author: Liu, Fei; Wang, Zixian; Li, Xiaofan; Zhang, Zhen; Yang, Yue; Chen, Junquan; Chen, Dinghua; Wu, Lingling; Liu, Xiangyu; Han, Sujun; Wang, Fangming; Wahafu, Wasilijiang; Gao, Yibo; Ren, Shancheng; Xing, Nianzeng; Cai, Guangyan; Chen, Xiangmei Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 2, pp. 214-224. DOI: 10.1002/cac2.12396 PubMed DOI |
| 9. | Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin Author: Zhao, Yuanyuan; Zhao, Bing; Chen, Gang; Chen, Yinlan; Liao, Zijun; Zhang, Haiming; Feng, Weineng; Li, Yinyin; Weng, Heng; Li, Weidong; Zhou, Yuefen; Ren, Biyong; Lu, Yanda; Chen, Jianhua; Liu, Zhenteng; Su, Zhenzhong; Wang, Wenliang; Zhang, Li Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 2, pp. 246-256. DOI: 10.1002/cac2.12397 PubMed DOI |
| 10. | Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial Author: Lin, Qing; Zheng, Shangyou; Yu, Xianjun; Chen, Meifu; Zhou, Yu; Zhou, Quanbo; Hu, Chonghui; Gu, Jing; Xu, Zhongdong; Wang, Lin; Liu, Yimin; Liu, Qingyu; Wang, Min; Li, Guolin; Cheng, He; Zhou, Dongkai; Liu, Guodong; Fu, Zhiqiang; Long, Yu; Li, Yixiong; Wang, Weilin; Qin, Renyi; Li, Zhihua; Chen, Rufu Journal: CANCER COMMUNICATIONS. 2023; Vol. 43, Issue 2, pp. 257-275. DOI: 10.1002/cac2.12399 PubMed DOI |
|
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
